TY - JOUR
T1 - 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)
AU - Knuuti, Juhani
AU - Wijns, William
AU - Saraste, Antti
AU - Capodanno, Davide
AU - Barbato, Emanuele
AU - Funck-Brentano, Christian
AU - Prescott, Eva
AU - Storey, Robert F
AU - Deaton, Christi
AU - Cuisset, Thomas
AU - Agewall, Stefan
AU - Dickstein, Kenneth
AU - Edvardsen, Thor
AU - Escaned, Javier
AU - Gersh, Bernard J
AU - Svitil, Pavel
AU - Gilard, Martine
AU - Hasdai, David
AU - Hatala, Robert
AU - Mahfoud, Felix
AU - Masip, Josep
AU - Muneretto, Claudio
AU - Valgimigli, Marco
AU - Achenbach, Stephan
AU - Bax, Jeroen J
AU - ESC Scientific Document Group
PY - 2020/1/14
Y1 - 2020/1/14
N2 - Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.
AB - Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.
KW - Angina pectoris
KW - Anti-ischaemic drugs
KW - Antithrombotic therapy
KW - Chronic coronary syndromes
KW - Coronary artery disease
KW - Diagnostic testing
KW - Guidelines
KW - Imaging
KW - Lifestyle modifications
KW - Lipid-lowering drugs
KW - Microvascular angina
KW - Myocardial ischaemia
KW - Myocardial revascularization
KW - Risk assessment
KW - Screening
KW - Vasospastic angina
KW - coronary artery disease
KW - risk assessment
KW - screening
KW - myocardial ischaemia
KW - vasospastic angina
KW - anti-ischaemic drugs
KW - angina pectoris
KW - diagnostic testing
KW - antithrombotic therapy
KW - imaging
KW - lipid-lowering drugs
KW - microvascular angina
KW - lifestyle modifications
KW - myocardial revascularization
KW - chronic coronary syndromes
UR - http://www.scopus.com/inward/record.url?scp=85077946639&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehz425
DO - 10.1093/eurheartj/ehz425
M3 - Review
C2 - 31504439
SN - 0195-668X
VL - 41
SP - 407
EP - 477
JO - European Heart Journal
JF - European Heart Journal
IS - 3
ER -